Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Clarity Pharmaceuticals Ltd. ( (AU:CU6) ).
Clarity Pharmaceuticals Ltd has announced a proposed issue of 48,485,212 ordinary fully paid securities, with the issue date set for July 28, 2025. This move is part of a placement or other type of issue, which may impact the company’s market positioning and provide additional capital for its operations, potentially influencing stakeholder interests.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$8.20 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd is a company operating in the pharmaceutical industry, focusing on the development and commercialization of radiopharmaceuticals for the treatment of serious diseases. The company is listed on the Australian Securities Exchange (ASX) under the code CU6.
Average Trading Volume: 2,986,894
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$1.33B
See more insights into CU6 stock on TipRanks’ Stock Analysis page.